Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation

Bibliography

• Boeckh M, Erard V, Zerr D, Englund J. Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant 2005;9(Suppl 7):48-54
   PubMedGoogle Scholar
• Peck AJ, Englund JA, Kuypers J, Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007;110:1681-8
   PubMed Web of Science ®Google Scholar
• Zerr DM, Corey L, Kim HW, Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005;40:932-40
   PubMed Web of Science ®Google Scholar
• Bruno B, Gooley T, Hackman RC, Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol Blood Marrow Transplant 2003;9:341-52
   PubMed Web of Science ®Google Scholar
• Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 2005;128:135-44
   PubMed Web of Science ®Google Scholar
• Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 2008;86:1327-39
   PubMed Web of Science ®Google Scholar
• Whimbey E, Champlin RE, Couch RB, Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778-82
   PubMed Web of Science ®Google Scholar
• La Rosa AM, Champlin RE, Mirza N, Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001;32:871-6
   PubMed Web of Science ®Google Scholar
• Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 2008;143:169-79
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-58
   PubMed Web of Science ®Google Scholar
• Flomenberg P, Babbitt J, Drobyski WR, Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994;169:775-81
   PubMed Web of Science ®Google Scholar
• Myers GD, Krance RA, Weiss H, Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005;36(11):1001-8
   PubMed Web of Science ®Google Scholar
• Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007;12:627-38
   PubMed Web of Science ®Google Scholar
• Giraud G, Priftakis P, Bogdanovic G, BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. Bone Marrow Transplant 2008;41:737-42
   PubMed Web of Science ®Google Scholar
• Martino R, Porras RP, Rabella N, Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005;11:781-96
   PubMed Web of Science ®Google Scholar
• Egli A, Binggeli S, Bodaghi S, Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007;22(Suppl 8): viii72-82
   Google Scholar
• Ginevri F, Azzi A, Hirsch HH, Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007;7:2727-35
   PubMed Web of Science ®Google Scholar
• de Pagter PJ, Schuurman R, Meijer E, Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. J Clin Virol 2008;43:361-6
   PubMed Web of Science ®Google Scholar
• de Pagter PJ, Schuurman R, Visscher H, Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008;14:831-9
   PubMed Web of Science ®Google Scholar
• Porter DL, Roth MS, McGarigle C, Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6
   PubMed Web of Science ®Google Scholar
• Porter DL, Collins RH Jr, Shpilberg O, Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999;5:253-61
   PubMedGoogle Scholar
• Kolb H-J, Schattenberg A, Goldman JM, Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood 1995;86:2041-50
   PubMed Web of Science ®Google Scholar
• Collins RH, Jr., Shpilberg O, Drobyski WR, Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44
   PubMed Web of Science ®Google Scholar
• Hromas R, Cornetta K, Srour E, Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994;84:1689-90
   PubMed Web of Science ®Google Scholar
• Papadopoulos EB, Ladanyi M, Emanuel D, Infusions of donor leukocytes to treat epstein–barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91
   PubMed Web of Science ®Google Scholar
• MacKinnon S, Papadopoulos EB, Carabasi MH, Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995;15:591-4
   PubMed Web of Science ®Google Scholar
• Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994;331:679-80
   PubMed Web of Science ®Google Scholar
• Guinan EC, Boussiotis VA, Neuberg D, Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704-14
   PubMed Web of Science ®Google Scholar
• Davies JK, Gribben JG, Brennan LL, Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 2008;112:2232-41
   PubMed Web of Science ®Google Scholar
• Powles R, Singhal S, Treleaven J, Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998;91:3481-6
   PubMed Web of Science ®Google Scholar
• Comoli P, Locatelli F, Moretta A, Human alloantigen-specific anergic cells induced by a combination of CTLA4-Ig and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone Marrow Transplant 2001;27:1263-73
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 1998;102:473-82
   PubMed Web of Science ®Google Scholar
• Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol 1999;163:3684-91
   PubMed Web of Science ®Google Scholar
• Rezvani K, Mielke S, Ahmadzadeh M, High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006;108:1291-7
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Eder R, Kunz-Schughart LA, Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood 2004;104:895-903
   PubMed Web of Science ®Google Scholar
• Trzonkowski P, Bieniaszewska M, Juscinska J, First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127– T regulatory cells. Clin Immunol 2009;133(1):22-6
   PubMed Web of Science ®Google Scholar
• Amrolia PJ, Muccioli-Casadei G, Yvon E, Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 2003;102:2292-9
   PubMed Web of Science ®Google Scholar
• Amrolia PJ, Mucioli-Casadei G, Huls H, Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. Cytotherapy 2005;7:116-25
   PubMedGoogle Scholar
• Mielke S, Nunes R, Rezvani K, A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008;111:4392-402
   PubMed Web of Science ®Google Scholar
• Nonn M, Herr W, Khan S, Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Transplantation 2008;86:1427-35
   PubMed Web of Science ®Google Scholar
• Solomon SR, Tran T, Carter CS, Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation. Cytotherapy 2002;4:395-406
   PubMed Web of Science ®Google Scholar
• Solomon SR, Mielke S, Savani BN, Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005;106:1123-29
   PubMed Web of Science ®Google Scholar
• Fehse B, Frerk O, Goldmann M, Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 2000;109:644-51
   PubMed Web of Science ®Google Scholar
• Mavroudis DA, Jiang YZ, Hensel N, Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996;17:793-9
   PubMed Web of Science ®Google Scholar
• van Dijk AM, Kessler FL, Stadhouders-Keet SA, Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br J Haematol 1999;107:169-75
   PubMed Web of Science ®Google Scholar
• Davies JK, Koh MB, Lowdell MW. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant 2004;10:259-68
   PubMed Web of Science ®Google Scholar
• Wehler TC, Nonn M, Brandt B, Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007;109:365-73
   PubMed Web of Science ®Google Scholar
• Hartwig UF, Nonn M, Khan S, Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 2006;37:297-305
   PubMed Web of Science ®Google Scholar
• Hartwig UF, Nonn M, Khan S, Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008;14:99-109
   PubMed Web of Science ®Google Scholar
• Sathe A, Ortega SB, Mundy DI, In vitro methotrexate as a practical approach to selective allodepletion. Biol Blood Marrow Transplant 2007;13:644-54
   PubMed Web of Science ®Google Scholar
• Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002;99:3083-8
   PubMed Web of Science ®Google Scholar
• Perruccio K, Topini F, Tosti A, Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008;40:76-83
   PubMed Web of Science ®Google Scholar
• Guimond M, Balassy A, Barrette M, P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells. Blood 2002;100:375-82
   PubMed Web of Science ®Google Scholar
• Amrolia PJ, Muccioli-Casadei G, Huls H, Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006;108:1797-808
   PubMed Web of Science ®Google Scholar
• Andre-Schmutz I, Le DF, Hacein-Bey-Abina S, Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002;360:130-7
   PubMed Web of Science ®Google Scholar
• Small TN, Papadopoulos EB, Boulad F, Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467-80
   PubMed Web of Science ®Google Scholar
• MacKinnon S, Papadopoulos EB, Carabasi MH, Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8
   PubMed Web of Science ®Google Scholar
• Tan LC, Gudgeon N, Annels NE, A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-35
   PubMed Web of Science ®Google Scholar
• Gillespie GM, Wills MR, Appay V, Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors. J Virol 2000;74:8140-50
   PubMed Web of Science ®Google Scholar
• Leen AM, Sili U, Savoldo B, Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004;103:1011-19
   PubMed Web of Science ®Google Scholar
• Bonini C, Ciceri F, Marktel S, Abrogation of GvHD and early immune reconstitution after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hematopoietic stem cell transplantation. Blood 2002;100(11):115a
   Google Scholar
• Bonini C, Ferrari G, Verzeletti S, HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft versus leukemia. Science 1997;276:1719-24
   PubMed Web of Science ®Google Scholar
• Ciceri F, Bonini C, Marktel S, Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-707
   PubMed Web of Science ®Google Scholar
• Munshi NC, Govindarajan R, Drake R, Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997;89:1334-40
   PubMed Web of Science ®Google Scholar
• Traversari C, Marktel S, Magnani Z, The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007;109:4708-15
   PubMed Web of Science ®Google Scholar
• Straathof KC, Pule MA, Yotnda P, An inducible caspase 9 safety switch for T-cell therapy. Blood 2005;105:4247-54
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-24
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44
   PubMed Web of Science ®Google Scholar
• Peggs KS, Verfuerth S, Pizzey A, Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-7
   PubMed Web of Science ®Google Scholar
• Micklethwaite KP, Clancy L, Sandher U, Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008;112:3974-81
   PubMed Web of Science ®Google Scholar
• Peggs K, Verfuerth S, MacKinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001;97:994-1000
   PubMed Web of Science ®Google Scholar
• Kuehnle I, Huls MH, Liu Z, CD20 monoclonal antibody (rituximab) for therapy of epstein–barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-5
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CY, Li C, Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, Use of gene-modified virus-specific T lymphocytes to control epstein-barr virus-related lymphoproliferation. Lancet 1995;345:9-13
   PubMed Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CY, Infusion of cytotoxic T cells for the prevention and treatment of epstein–barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-55
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou JZ, Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807-14
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M, Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007;7:1648-55
   PubMed Web of Science ®Google Scholar
• Gavioli R, Kurilla MG, de Campos-Lima PO, Multiple HLA-A11-restricted cytotoxic T lymphocyte epitopes of different immunogenicities in the epstein-barr virus-encoded nuclear antigen 4. J Virol 1993;67:1572-8
   PubMed Web of Science ®Google Scholar
• Gavioli R, de Campos-Lima PO, Kurilla M, Recognition of the epstein-barr virus-encoded nuclear antigens, EBNA4 and EBNA6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in burkitt lymphoma. Proc Natl Acad Sci USA 1992;89:5862-6
   PubMed Web of Science ®Google Scholar
• Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from epstein–barr virus. Annu Rev Immunol 2007;25:587-617
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Ng CYC, Smith CA, An epstein–barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001;97:835-43
   PubMed Web of Science ®Google Scholar
• Leen A, Ratnayake M, Foster A, Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother 2007;30:96-107
   PubMed Web of Science ®Google Scholar
• Sili U, Huls MH, Davis AR, Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocytes using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother 2003;26:241-56
   PubMed Web of Science ®Google Scholar
• Leen AM, Myers GD, Sili U, Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Khalil M, Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008;82:546-54
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Myers GD, Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and epstein–barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood 2009;114(19):4283-92
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2009: published online 30 October 2009, doi 10.1182/blood-2009-08-239186
   Google Scholar
• Kern F, Faulhaber N, Frommel C, Analysis of CD8 T cell reactivity to cytomegalovirus using protein- spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000;30:1676-82
   PubMed Web of Science ®Google Scholar
• Kedl RM, Rees WA, Hildeman DA, T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000;192:1105-13
   PubMed Web of Science ®Google Scholar
• Kedl RM, Schaefer BC, Kappler JW, Marrack P. T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 2002;3:27-32
   PubMed Web of Science ®Google Scholar
• Cobbold M, Khan N, Pourgheysari B, Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Matthes-Martin S, Richard C, Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006;134:64-76
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Thomson K, Verfuerth S, Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis 2008;40:63-7
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Ainsworth J, Cobbold M, Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 2001;97:1232-40
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Lang P, Hamprecht K, Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol 2004;32:282-9
   PubMed Web of Science ®Google Scholar
• Fujita Y, Leen AM, Sun J, Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008;31(7):665-74
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Christin AS, Vera JF, Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009;17(9):1616-25
   PubMed Web of Science ®Google Scholar
• Rauser G, Einsele H, Sinzger C, Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004;103:3565-72
   PubMed Web of Science ®Google Scholar
• Berger C, Jensen MC, Lansdorp PM, Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305
   PubMed Web of Science ®Google Scholar
• Landais E, Morice A, Long HM, EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses. J Immunol 2006;177:1427-33
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Fisicaro P, Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 2005;201:675-80
   PubMed Web of Science ®Google Scholar
• Elkington R, Khanna R. Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: implications for graft-versus-host disease. Blood 2005;105:1362-4
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Taylor C, Treatment of epstein–barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-42
   PubMed Web of Science ®Google Scholar
• Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic epstein–barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002;118:799-808
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-31
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Wilkie GM, Dua U, Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007;7:1293-9
   PubMed Web of Science ®Google Scholar
• Carswell KS, Papoutsakis ET. Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: shear, proliferation, and the IL-2 receptor. Biotechnol Bioeng 2000;68:328-38
   PubMed Web of Science ®Google Scholar
• Foster AE, Forrester K, Gottlieb DJ, Large-scale expansion of cytomegalovirus-specific cytotoxic T cells in suspension culture. Biotechnol Bioeng 2004;85:138-46
   PubMed Web of Science ®Google Scholar
• Knazek RA, Wu YW, Aebersold PM, Rosenberg SA. Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors. J Immunol Methods 1990;127:29-37
   PubMed Web of Science ®Google Scholar
• Malone CC, Schiltz PM, Mackintosh AD, Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer. Cancer Biother Radiopharm 2001;16:381-90
   PubMed Web of Science ®Google Scholar
• Hollyman D, Stefanski J, Przybylowski M, Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009;32:169-80
   PubMed Web of Science ®Google Scholar
• Tran CA, Burton L, Russom D, Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. J Immunother 2007;30:644-54
   PubMed Web of Science ®Google Scholar
• Vera JF, Brenner LJ, Gerdemann U, Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex). J Immunother 2010 (In Press)
   PubMed Web of Science ®Google Scholar
• Park KD, Marti L, Kurtzberg J, Szabolcs P. In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006;108:1770-3
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Cruz CR, Savoldo B, Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114(9):1958-67
   PubMed Web of Science ®Google Scholar
• Howard DS, Phillips II GL, Reece DE, Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999;29:1494-501
   PubMed Web of Science ®Google Scholar
• Runde V, Ross S, Trenschel R, Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 2001;28:51-7
   PubMed Web of Science ®Google Scholar
• Hale GA, Heslop HE, Krance RA, Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999;23:277-82
   PubMed Web of Science ®Google Scholar
• Funk GA, Gosert R, Hirsch HH. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007;7:460-72
   PubMed Web of Science ®Google Scholar
• Schenk T, Strahm B, Kontny U, Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 2007;13:1425-7
   PubMed Web of Science ®Google Scholar
• Kumar D, Tellier R, Draker R, Severe acute respiratory syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003;3:977-81
   PubMed Web of Science ®Google Scholar
• Farcas GA, Poutanen SM, Mazzulli T, Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005;191:193-7
   PubMed Web of Science ®Google Scholar
• Xu J, Zhong S, Liu J, Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis 2005;41:1089-96
   PubMed Web of Science ®Google Scholar
• Garbino J, Crespo S, Aubert JD, A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection. Clin Infect Dis 2006;43:1009-15
   PubMed Web of Science ®Google Scholar
• Pene F, Merlat A, Vabret A, Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003;37:929-32
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Schulz TF, Welte T, Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009;87:1530-7
   PubMed Web of Science ®Google Scholar
• Harma M, Hockerstedt K, Krogerus L, Lautenschlager I. Pretransplant human herpesvirus 6 infection of patients with acute liver failure is a risk factor for posttransplant human herpesvirus 6 infection of the liver. Transplantation 2006;81:367-72
   PubMed Web of Science ®Google Scholar
• Benito N, Ricart MJ, Pumarola T, Infection with human herpesvirus 6 after kidney-pancreas transplant. Am J Transplant 2004;4:1197-9
   PubMed Web of Science ®Google Scholar
• Ogata M, Kikuchi H, Satou T, Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006;193:68-79
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Suga S, Asano Y, A prospective study of human herpesvirus-6 infection in renal transplantation. Transplantation 1992;54:879-83
   PubMed Web of Science ®Google Scholar
• Cole PD, Stiles J, Boulad F, Successful treatment of human herpesvirus 6 encephalitis in a bone marrow transplant recipient. Clin Infect Dis 1998;27:653-54
   PubMed Web of Science ®Google Scholar
• Rosenfeld CS, Rybka WB, Weinbaum D, Late graft failure due to dual bone marrow infection with variants A and B of human herpesvirus-6. Exp Hematol 1995;23:626-9
   PubMed Web of Science ®Google Scholar
• Singh N, Carrigan DR, Gayowski T, Marino IR. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997;64:674-8
   PubMed Web of Science ®Google Scholar
• Isegawa Y, Hara J, Amo K, Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol 2009;44:15-9
   PubMed Web of Science ®Google Scholar
• Wang LR, Dong LJ, Zhang MJ, Lu DP. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2008;42:673-7
   PubMed Web of Science ®Google Scholar
• Dzieciatkowski T, Przybylski M, Torosian T, Prevalence of human herpesvirus 6 antibodies and DNA in allogeneic stem cell transplant patients: two-year single centre experience. Arch Immunol Ther Exp (Warsz) 2008;56:201-6
   PubMed Web of Science ®Google Scholar
• Fischer SA, Graham MB, Kuehnert MJ, Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006;354:2235-49
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Lymphocytic choriomeningitis virus infection in organ transplant recipients–Massachusetts, Rhode Island, 2005. MMWR Morb Mortal Wkly Rep 2005;54:537-9
   PubMedGoogle Scholar
• Palacios G, Druce J, Du L, A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358:991-8
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Brief report. Lymphocytic choriomeningitis virus transmitted through solid organ transplantation–Massachusetts, 2008. MMWR Morb Mortal Wkly Rep 2008;57:799-801
   PubMedGoogle Scholar
• Wong RD, Goetz MB. Clinical and laboratory features of measles in hospitalized adults. Am J Med 1993;95:377-83
   PubMed Web of Science ®Google Scholar
• Baas MC, van Donselaar KA, Florquin S, Mumps: not an innocent bystander in solid organ transplantation. Am J Transplant 2009;9(9):2186-9
   PubMed Web of Science ®Google Scholar
• Park SB, Jin KB, Hwang EA, Case of adult mumps infection after renal transplantation. Transplant Proc 2008;40:2442-3
   PubMed Web of Science ®Google Scholar
• Turner A, Jeyaratnam D, Haworth F, Measles-associated encephalopathy in children with renal transplants. Am J Transplant 2006;6:1459-65
   PubMed Web of Science ®Google Scholar
• Sumino KC, Agapov E, Pierce RA, Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment. J Infect Dis 2005;192:1052-60
   PubMed Web of Science ®Google Scholar
• Larcher C, Geltner C, Fischer H, Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant 2005;24:1891-901
   PubMed Web of Science ®Google Scholar
• Richards A, Chuen JN, Taylor C, Acute respiratory infection in a renal transplant recipient. Nephrol Dial Transplant 2005;20:2848-50
   PubMed Web of Science ®Google Scholar
• Englund JA, Boeckh M, Kuypers J, Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006;144:344-9
   PubMed Web of Science ®Google Scholar
• Gerna G, Vitulo P, Rovida F, Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006;78:408-16
   PubMed Web of Science ®Google Scholar
• Debiaggi M, Canducci F, Sampaolo M, Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 2006;194:474-8
   PubMed Web of Science ®Google Scholar
• Raza K, Ismailjee SB, Crespo M, Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007;26:862-4
   PubMed Web of Science ®Google Scholar
• Hopkins P, McNeil K, Kermeen F, Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008;178:876-81
   PubMed Web of Science ®Google Scholar
• Dare R, Sanghavi S, Bullotta A, Diagnosis of human metapneumovirus infection in immunosuppressed lung transplant recipients and children evaluated for pertussis. J Clin Microbiol 2007;45:548-52
   PubMed Web of Science ®Google Scholar
• Kamble RT, Bollard C, Demmler G, Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant 2007;40:699-700
   PubMed Web of Science ®Google Scholar
• Elizaga J, Olavarria E, Apperley J, Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001;32:413-18
   PubMed Web of Science ®Google Scholar
• Vilchez RA, McCurry K, Dauber J, The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001;33:2004-8
   PubMed Web of Science ®Google Scholar
• Nichols WG, Corey L, Gooley T, Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001;98:573-8
   PubMed Web of Science ®Google Scholar
• Zambon M, Bull T, Sadler CJ, Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998;36:2289-93
   PubMed Web of Science ®Google Scholar
• Hohenthal U, Nikoskelainen J, Vainionpaa R, Parainfluenza virus type 3 infections in a hematology unit. Bone Marrow Transplant 2001;27:295-300
   PubMed Web of Science ®Google Scholar
• Cortez KJ, Erdman DD, Peret TC, Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001;184:1093-7
   PubMed Web of Science ®Google Scholar
• Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006;43:40-8
   PubMed Web of Science ®Google Scholar
• Klumpen HJ, Petersen EJ, Verdonck LF. Severe multiorgan failure after parvovirus B19 infection in an allogeneic stem cell transplant recipient. Bone Marrow Transplant 2004;34:469-70
   PubMed Web of Science ®Google Scholar
• Laurenz M, Winkelmann B, Roigas J, Severe parvovirus B19 encephalitis after renal transplantation. Pediatr Transplant 2006;10:978-81
   PubMed Web of Science ®Google Scholar
• Yango A Jr, Morrissey P, Gohh R, Wahbeh A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. Transpl Infect Dis. 2002;4:163-6
   PubMedGoogle Scholar
• Wasak-Szulkowska E, Grabarczyk P, Rzepecki P. Pure red cell aplasia due to parvovirus B19 infection transmitted probably through hematopoietic stem cell transplantation. Transpl Infect Dis 2008;10:201-25
   PubMed Web of Science ®Google Scholar
• Muetherig A, Christopeit M, Muller LP, Human parvovirus B19 infection with GvHD-like erythema in two allogeneic stem cell transplant recipients. Bone Marrow Transplant 2007;39:315-16
   PubMed Web of Science ®Google Scholar
• Plentz A, Hahn J, Holler E, Long-term parvovirus B19 viraemia associated with pure red cell aplasia after allogeneic bone marrow transplantation. J Clin Virol 2004;31:16-9
   PubMed Web of Science ®Google Scholar
• Barzon L, Murer L, Pacenti M, Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury. J Infect Dis 2009;199:372-80
   PubMed Web of Science ®Google Scholar
• Pinto V, Grandy J, Zambrano P, Severe anemia from parvovirus B19 infection in pediatric renal transplant recipients: two case reports. Transplant Proc 2008;40:3261-4
   PubMed Web of Science ®Google Scholar
• Biagini P, Dussol B, Touinssi M, Human parvovirus 4 in kidney transplant patients, France. Emerg Infect Dis 2008;14:1811-12
   PubMed Web of Science ®Google Scholar
• Ardalan MR, Shoja MM, Tubbs RS, Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus B19 infection. Am J Transplant 2008;8:1340-4
   PubMed Web of Science ®Google Scholar
• Waldman M, Kopp JB. Parvovirus-B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol 2007;3:540-50
   PubMedGoogle Scholar
• Whimbey E, Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 2000;20:232-55
   PubMedGoogle Scholar
• Ko JP, Shepard JA, Sproule MW, CT manifestations of respiratory syncytial virus infection in lung transplant recipients. J Comput Assist Tomogr 2000;24:235-41
   PubMed Web of Science ®Google Scholar
• Harrington RD, Hooton TM, Hackman RC, An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93
   PubMed Web of Science ®Google Scholar
• Lopez-Medrano F, Aguado JM, Lizasoain M, Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007;84:851-6
   PubMed Web of Science ®Google Scholar
• Stelzmueller I, Wiesmayr S, Swenson BR, Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis 2007;9:281-5
   PubMed Web of Science ®Google Scholar
• Tumgor G, Arikan C, Aydin U, Effect of rotavirus on serum tacrolimus level in pediatric liver transplant recipients. Pediatr Int 2008;50:592-3
   PubMed Web of Science ®Google Scholar
• Eisengart LJ, Chou PM, Iyer K, Rotavirus infection in small bowel transplant: a histologic comparison with acute cellular rejection. Pediatr Dev Pathol 2009;12:85-8
   PubMed Web of Science ®Google Scholar
• Barshes NR, Agee EE, Zgabay T, West Nile Virus encephalopathy following pancreatic islet transplantation. Am J Transplant 2006;6:3037
   PubMed Web of Science ®Google Scholar
• Armali Z, Ramadan R, Chlebowski A, Azzam ZS. West Nile meningo-encephalitis infection in a kidney transplant recipient. Transplant Proc 2003;35:2935-6
   PubMed Web of Science ®Google Scholar
• Shepherd JC, Subramanian A, Montgomery RA, West Nile virus encephalitis in a kidney transplant recipient. Am J Transplant 2004;4:830-3
   PubMed Web of Science ®Google Scholar
• DeSalvo D, Roy-Chaudhury P, Peddi R, West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. Transplantation 2004;77:466-9
   PubMed Web of Science ®Google Scholar
• Kumar D, Prasad GV, Zaltzman J, Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004;77:399-402
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Marder BA, Levi ME, Naturally acquired west nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features. Arch Neurol 2004;61:1210-20
   PubMed Web of Science ®Google Scholar
• Penn RG, Guarner J, Sejvar JJ, Persistent neuroinvasive West Nile virus infection in an immunocompromised patient. Clin Infect Dis 2006;42:680-3
   PubMed Web of Science ®Google Scholar
• Hong DS, Jacobson KL, Raad II, West nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis 2003;37:1044-9
   PubMed Web of Science ®Google Scholar
• Hiatt B, DesJardin L, Carter T, A fatal case of West Nile virus infection in a bone marrow transplant recipient. Clin Infect Dis 2003;37:e129-31
   Google Scholar
• Ziedina I, Folkmane I, Chapenko S, Reactivation of BK virus in the early period after kidney transplantation. Transplant Proc 2009;41:766-8
   PubMed Web of Science ®Google Scholar
• Munoz GP. BK virus in liver transplant recipients: a prospective study. Transplant Proc 2009;41:1033-7
   PubMed Web of Science ®Google Scholar
• Boldorini R, Allegrini S, Miglio U, Detection, distribution, and pathologic significance of BK virus strains isolated from patients with kidney transplants, with and without polyomavirus-associated nephropathy. Arch Pathol Lab Med 2009;133:766-74
   PubMed Web of Science ®Google Scholar
• Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008;13:569-74
   PubMed Web of Science ®Google Scholar
• Comoli P, Binggeli S, Ginevri F, Hirsch HH. Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis 2006;8:86-94
   PubMed Web of Science ®Google Scholar